Cara Therapeutics | CARA - Pre Tax Profit


Cara Therapeutics reported $-4.91M in Pre-Tax Profit for its fiscal quarter ending in March of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Assertio Holdings USD -2.88M 648K Sep/2024
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Cassava Sciences USD -10.81M 33.41M Sep/2025
Chugai Pharma JPY 160.2B 9.71B Mar/2026
Cipla INR 7.49B 4.2B Mar/2026
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD 56.84M 63.78M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pacira USD 571K 8.95M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
RedHill Biopharma USD -1.54M 12M Jun/2024
Supernus Pharmaceuticals USD -5.95M 4.04M Mar/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024